Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: PORTUGAL - REVIEW
The macroenvironment remains tough for the Portuguese pharmaceutical market. Politically, the Prime Minister aims to create a more efficient state and comply with the bail-out commitments signed by the previous socialist government. The austerity programme is expected to remain high on his agenda. Economically, the Economist Intelligence Unit (EIU) believes that economic and fiscal policy will be shaped by the bail-out agreement signed with the EU and the IMF. There are signs that public hospitals will be affected as part of the country's effort to reduce its budget deficit. Legally, IPR regulations are harmonised with EU procedures. Demographically, Portugal has one of the smallest populations in Western Europe, but the EIU projects that the number of people aged 65 years and over will increase to represent nearly a fifth of the total population in 2016.
Pharmaceutical sales growth will be negligible in the forecast period. In US dollar terms, pharmaceutical sales in Portugal are expected to rise in 2011, due to a weaker exchange of the US dollar against the euro, and to fall between 2012 and 2016, affected by a stronger projected exchange rate. In euro terms, pharmaceutical sales are projected to increase modestly in the forecast period, due to the government's cost-containment measures, particularly price cuts. In 2016, the Portuguese pharmaceutical market will rank 12th in Western Europe. In per capita terms, Portugal will have the lowest pharmaceutical expenditure. The Minister of Health is very keen to encourage further generic consumption in the forecast period.
Improved regulation has encouraged generic sales in Portugal, but prices have been slashed in recent years. Contrary to what happens in other markets, generic sales in Portugal have a higher market share in value than in volume. The generic market is very fragmented, with many companies that have a low market share. Leading national generic producers include Farmoz (part of Tecnimede), Generis (part of Farma-APS), Medinfar, Hovione, Bluepharma and ToLife. Foreign generic producers include Mylan, ratiopharm (now part of Teva), Alter, Fresenius Kabi (via Labesfal), Stada, Actavis and Winthrop.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
The Pharmaceutical Market: Portugal published by Espicom Business Intelligence in January 31, 2013. This report consists of 91 Pages and the price starts from US $ 1295.
The contents of this page may be different from the latest version. Please contact us for details.
